Tempus AI’s chief accounting officer sells shares worth $290,265

Published 07/02/2025, 23:38
Tempus AI’s chief accounting officer sells shares worth $290,265

Ryan M. Bartolucci, Chief Accounting Officer at Tempus AI , Inc. (NASDAQ:TEM), recently sold a significant portion of company stock, according to a recent SEC filing. On February 5, Bartolucci sold 1,858 shares of Class A Common Stock at an average price of $67.57, amounting to approximately $125,545. This transaction was part of a mandatory sale to cover tax obligations related to restricted stock units. The sale comes amid strong momentum for TEM shares, which have surged 92.51% year-to-date. InvestingPro data indicates the stock is currently trading in overbought territory.

On the following day, February 6, Bartolucci executed another sale, disposing of 2,320 shares at a price of $71 per share, totaling around $164,720. This transaction was conducted under a pre-established Rule 10b5-1 trading plan adopted on June 14, 2024. The company, currently valued at $10.23 billion, maintains a healthy liquidity position with a current ratio of 2.69.

Following these transactions, Bartolucci holds 53,059 shares of Tempus AI. These sales were part of a structured plan and not discretionary, as noted in the filing. InvestingPro analysis reveals 8 additional key insights about TEM’s financial health and valuation metrics.

In other recent news, Tempus AI has been making significant strides in the AI healthcare sector. The company recently upgraded its stock rating and increased the price target to $74, as reported by TD Cowen. This upgrade followed Tempus AI’s acquisition of Ambry Genetics, which has added a profitable germline testing laboratory with over $300 million in revenue to Tempus AI’s portfolio. Analysts at TD Cowen believe this strategic move will enhance Tempus AI’s product offerings and open up new markets.

In addition to the acquisition, Tempus AI has launched a personal health concierge app named Olivia. This application aims to centralize patient health data and provide actionable AI-driven insights, furthering the company’s commitment to improving patient outcomes through technology. Olivia’s features include synthesizing patient data into a comprehensive profile and summarizing physician appointments, among others.

Recent developments also include a partnership between Genialis and Tempus AI. Genialis, a company specializing in RNA biomarkers, has entered a multi-year agreement with Tempus AI to validate new RNA-based biomarker algorithms. This collaboration is expected to contribute to the advancement of precision medicine and patient care sectors.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers
© 2007-2025 - Fusion Media Limited. All Rights Reserved.